GRACEcast
Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.
Visit Show Website http://cancerGRACE.org/Recently Aired
-
HD
HPV in Head and Neck Cancer, Part 1: What is it and What Does it Mean? (video)
Dr. Jared Weiss from the University of North Carolina, Chapel ...
Dr. Jared Weiss from the University of North Carolina, Chapel Hill introduces us to the human papilloma virus and its role as a cause and relevant prognostic factor for head and neck cancer (HNSCC).
-
HD
HPV in Head and Neck Cancer, Part 1: What is it and What Does it Mean? (audio)
GRACE, cancerGRACE, GRACEcast, Jared Weiss, Unveristy of North Carolina-Chapel Hill, ...
GRACE, cancerGRACE, GRACEcast, Jared Weiss, Unveristy of North Carolina-Chapel Hill, UNC-Chapel Hill, induction therapy, neoadjuvant therapy, head and neck cancer, HNSCC, carbplatin, paclitaxel, cetuximab, Taxol, Erbitux, weekly
-
HD
Induction Chemotherapy for Head and Neck Cancer, Part 2: New Concepts Moving Forward (video)
Dr. Jared Weiss from the University of North Carolina, reviews ...
Dr. Jared Weiss from the University of North Carolina, reviews several options as induction therapy for head and neck cancer and focuses on the potential appeal and tolerability of the combination of weekly carboplatin and paclitaxel with cetuximab.
-
HD
Induction Chemotherapy for Head and Neck Cancer, Part 2: New Concepts Moving Forward (audio)
Dr. Jared Weiss from the University of North Carolina, reviews ...
Dr. Jared Weiss from the University of North Carolina, reviews several options as induction therapy for head and neck cancer and focuses on the potential appeal and tolerability of the combination of weekly carboplatin and paclitaxel with cetuximab.
-
HD
Induction Chemotherapy for Head and Neck Cancer, Part 1: Defining the Challenges (video)
Dr. Jared Weiss from the University of North Carolina, Chapel ...
Dr. Jared Weiss from the University of North Carolina, Chapel Hill reviews the rationale for induction chemotherapy before surgery for head and neck cancer and highlights the early work that led to the emergence of the TPF regimen in this setting.
-
HD
Induction Chemotherapy for Head and Neck Cancer, Part 1: Defining the Challenges (audio)
Dr. Jared Weiss from the University of North Carolina, Chapel ...
Dr. Jared Weiss from the University of North Carolina, Chapel Hill reviews the rationale for induction chemotherapy before surgery for head and neck cancer and highlights the early work that led to the emergence of the TPF regimen in this setting.
-
HD
Dr. Ravi Salgia: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing?
Dr. Ravi Salgia, from the University of Chicago, describes which ...
Dr. Ravi Salgia, from the University of Chicago, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.
-
HD
Dr. Sarah Goldberg: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Dr. Sarah Goldberg gives her view on more widespread availability ...
Dr. Sarah Goldberg gives her view on more widespread availability of new mutation tests, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for other LC subtypes.
-
HD
Dr. Bob Doebele on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment
Dr. Bob Doebele from the University of Colorado, provides his ...
Dr. Bob Doebele from the University of Colorado, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.
-
HD
Drs. Ross Camidge and Corey Langer on "Which patients do you send molecular marker testing for?"
Drs. Ross Camidge and Corey Langer describe which patients with ...
Drs. Ross Camidge and Corey Langer describe which patients with advanced NSCLC they seek molecular marker testing on.
